LSPN Europe: English contract law still ‘fit for purpose’ despite Brexit
English law remains fit for purpose in international contracts in spite of Brexit, heard attendees at Life Sciences Patent Network Europe today, November 21.
EU General Court sides with Merck in TM opposition
A German individual has lost an appeal before the tribunal of the EU General Court, after his trademark registration was opposed by Merck.
Drop prices or lose patent rights, say White House hopefuls
US presidential candidates Bernie Sanders and Cory Booker have tabled a bill that would force drug companies to adhere to government-set prices-or risk losing patent exclusivity.
UKIPO dismisses Swiss IP office’s bid to stop Indian pharma TM
The Swiss Federal Institute of Intellectual Property has failed to stop an Indian pharmaceutical and medicine wholesaler from registering the trademark ‘Swisslife Forever’ at the UK Intellectual Property Office.
Russian government approves compulsory drug licensing bill
The Russian government has endorsed legislation that would allow it to employ compulsory drug licensing in emergencies.
Roche buys fibrotic diseases biotech in $1.4bn deal
Switzerland-based Roche has agreed to acquire Promedior and its portfolio of molecules for serious fibrotic diseases.
Regents of the University of Michigan file patent suit against microscope maker
The Regents of the University of Michigan have sued an optical microscope manufacturer for allegedly infringed one of its patents.
EPO successful in cutting opposition times: Mewburn Ellis
The European Patent Office has made strides in streamlining its opposition procedures, new data from Mewburn Ellis has shown.
Chinese state-owned chemical firm in fungicide patent suit
A Chinese state-owned chemical firm is suing US crop protection products company Atticus for patent infringement.
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
Seattle Genetics has asked the American Arbitration Association to help resolve a dispute with Daiichi Sankyo, alleging that the Japanese pharma company used its technology to create a number of drugs.
